

Date: August 20, 2025

BSE Limited

P. J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai - 400 051
NSE Symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations and further to our intimation dated April 23, 2025, we hereby inform that today, Piramal Healthcare Inc. a material step-down wholly owned subsidiary of the Company, has completed subscription of 1,903 optionally convertible redeemable preference shares of face value of USD 100,000 each aggregating to USD 190,300,000 (₹ 1,626.49 Crore) of PPL Pharma Inc., step-down wholly owned subsidiary of the Company.

Kindly take the above on record.

Yours truly,

For Piramal Pharma Limited

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000; **Email:** shareholders.ppl@piramal.com

piramalpharma.com